Recursion Pharmaceuticals (RXRX) Shares Outstanding (Weighted Average) (2020 - 2026)

Recursion Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 7 years, with the latest figure at $529.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 31.42% year-over-year to $529.3 million; the trailing twelve-month figure through Mar 2026 stood at $529.3 million (up 31.42% YoY), and the FY2025 full-year result was $447.4 million, up 63.18% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $529.3 million, up from $447.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $529.3 million in Q1 2026, with the low at $170.7 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $277.7 million across 5 years, with a median of $236.0 million in 2024.
• The largest YoY upside for Shares Outstanding (Weighted Average) was 640.98% in 2022 against a maximum downside of 2.13% in 2022.
• Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $175.5 million in 2022, then increased by 18.41% to $207.9 million in 2023, then surged by 31.92% to $274.2 million in 2024, then soared by 63.18% to $447.4 million in 2025, then rose by 18.29% to $529.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $529.3 million (Q1 2026), $447.4 million (Q4 2025), and $422.6 million (Q3 2025), per Business Quant data.